Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH case-control study.

5. Bertolaccini ML, Sanna G, Ralhan S, Gennari L, Merrill J, Khamashta M, et al. Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost 2003;90:636-41. 6. Nojima J, Kuratsune H, Suehisa E, Kavasaki T, Machii T, Kitani T, et al. Acquired activated protein C resistance associated with anti protein S antibody as a strong risk factor for DVT in non-SLE patients. Throm Haemost 2002;88:716-22. 7. Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchioli R, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007;110:1178-83. 8. Sorice M, Arcieri P, Griggi T, Circella A, Misasi R, Lenti L, et al. Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency. Thromb Haemost 1996;75: 555-9. 9. Guermazi S, Regnault V, Gorgi Y, Ayed K, Lecompte T, Dellagi K. Further evidence for the presence of anti-protein S autoantibodies in patients with systemic lupus erythematosus. Blood Coagul Fibrinolylis 2000;11:491-8. 10. Regnault V, Boehlen F, Ozsahin H, Wahl D, de Groot P, Lecompte T, et al. Antiprotein S antibodies following a varicella infection: detection, characterisation and influence on thrombin generation. J Thromb Haemost 2005;3:1243-9.